To date, molecular testing has been widely studied for thyroid cancer with BRAF mutation as the most commonly used biomarker for preoperative diagnosis using FNAB specimens (Nikiforova and Nikiforov, 2009). The gene discussed is BRAF; the disease is thyroid cancer.